Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Doc Bones who wrote (2045)	11/15/2000 9:03:29 AM
From: Biomaven	Read Replies (2) of 52153

Thanks, Doc. Bit of a stretch posting this here, but the FRX thread is out of the question, as a money-making $11 Billion company it holds no interest for SI bio afficianados Actually I hold FRX, AZA and ELN, all not-quite-pharmas. I've held FRX since before Celexa was approved in the US, based on some prescient advice from a neuro-psychiatrist friend that Celexa would ultimately do as well in the US as it had in Europe. Celexa continues to go great guns, and memantine isn't in the FRX price at all. One caution with FRX is that at some point somebody is going to notice that Celexa doesn't have that much patent life left. These not-quite-pharmas have been strong through the recent turmoil. Not a bad place to be for those that can't stomach buying a real pharma. <g> Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next